Pharma Mar, S.A.

MCE PHM.MC

Pharma Mar, S.A. EBITDA Margin for the year ending December 31, 2023: 2.88%

Pharma Mar, S.A. EBITDA Margin is 2.88% for the year ending December 31, 2023, a -89.15% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Pharma Mar, S.A. EBITDA Margin for the year ending December 31, 2022 was 26.52%, a -41.45% change year over year.
Pharma Mar, S.A. EBITDA Margin for the year ending December 31, 2021 was 45.29%, a -21.60% change year over year.
Pharma Mar, S.A. EBITDA Margin for the year ending December 31, 2020 was 57.76%, a 523.30% change year over year.
Pharma Mar, S.A. EBITDA Margin for the year ending December 31, 2019 was -13.65%, a -133.55% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

MCE: PHM.MC

Pharma Mar, S.A.

CEO	Mr. Jose Maria Fernandez Sousa-Faro Ph.D.
IPO Date	Sept. 8, 2000
Location	Spain
Headquarters	Avenida de los Reyes, 1
Employees	509
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Key trends

Past 5 years